Glucosamine + Chondroitin + Msm + Hyaluronic Acid

Verify with FDA CVM →

16 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
16
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Glucosamine + Chondroitin + Msm + Hyaluronic Acid

Administration Routes

OralUnknown

Species Affected

Dog 15
Cat 1

Most Affected Breeds

Retriever - Labrador 3
Retriever (unspecified) 2
Terrier - Yorkshire 2
Pit Bull 2
Terrier (unspecified) 1
Spitz - Finnish 1
Chihuahua 1
Terrier - Boston 1
Beagle 1
Bulldog - French 1

Most Reported Reactions

Emesis 5
Vomiting 3
Weight gain 2
Behavioural disorder NOS 1
Sleepiness - neurological disorder 1
Decreased appetite 1
Lethargy (see also Central nervous system depression in 'Neurological') 1
Depression 1
Not eating 1
Other abnormal test result NOS 1
Urine abnormalities NOS 1
Musculoskeletal disorder NOS 1

Outcome Breakdown

Outcome Unknown
7 (43.8%)
Recovered/Normal
6 (37.5%)
Ongoing
3 (18.8%)

Data Summary

Metric Value
Total adverse event reports 16
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 2
Distinct breeds in reports 11
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Glucosamine + Chondroitin + Msm + Hyaluronic Acid Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 16 adverse event reports referencing Glucosamine + Chondroitin + Msm + Hyaluronic Acid, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Glucosamine + Chondroitin + Msm + Hyaluronic Acid. Reported administration routes include Oral, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Glucosamine + Chondroitin + Msm + Hyaluronic Acid reports are Dog (15 reports), Cat (1 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (3), Retriever (unspecified) (2), Terrier - Yorkshire (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Glucosamine + Chondroitin + Msm + Hyaluronic Acid are Emesis (5), Vomiting (3), Weight gain (2), Behavioural disorder NOS (1). Of the 16 reports with a coded outcome, Outcome Unknown is the leading category at 43.8%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Glucosamine + Chondroitin + Msm + Hyaluronic Acid.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial